Zhengda Tianqing Adamu monoantine submitted listing application Anrotini submitted 3 clinical applications!

From: Pharmaceutical MissionAccording to the Chinese State Drug Administration Drug Review Center (CDE) public information, Zheng Daqing today submitted the Adamu sing-it-againstre injection application, and TKI inhibitor Anrotinib 3 clinical trial applicationsAccording to public information, Zhengda Tianqing has been approved for sale in recent years, including the first generic drug injection of benzodiazepine hydrochloride and the treatment of rheumatoid arthritis drug tofalic cloth tabletsAt the same time, the company's innovative products are also worthy of attention, especially its investment in the field of anti-tumorToday, we will take stock of Zhengda Qing in the research products of the 1 new drugAdamu single antigen research products for Sumeile, is the world's first approved all-human anti-tumor necrosis factor monoclonal antibodies, which have been approved in China six indicationsInflammation overdoses in a variety of immuno-mediated diseases in humans are associated with tumor necrosis factor alpha (TNF-alpha), and Adamu monotogenesis selectively binds to TNF-alpha molecules, preventing them from attaching to healthy cells, thereby reducing the damage caused by excessive TNF-alphaBased on this principle, Adamu monotomare can be used to treat a variety of immunomediated diseasesAccording to CDE's official website, Zhengda Tianqing is the sixth Chinese company to submit an application for a listing of Adamu Mono, of which The products of BaiOtai and Haizheng Pharmaceuticals have been approved for listingAnrotinib is a new type of small molecule multi-target tyrosine kinase (TKI) inhibitor developed after more than 10 years, which can effectively inhibit VEGFR, PDGFR, FGFR, c-Kit and other kinases, with anti-tumor generation and inhibit tumor growth dual effectIn May 2018, Arotini was approved for the first time in China through a priority review process, and has been approved for three adaptations: third-line treatment of advanced non-small cell lung cancer, the treatment of soft tissue sarcoma, and the third-line treatment of small cell lung cancerIn January this year, the fourth new indication application for Anrotini was included in the list of priority review varietiesIt is worth mentioning that the drug has been approved "fast step" into China's national health insurance directoryAt present, Zhengda Tianqing is in a number of clinical trials to study the effectiveness of the aronitine and the combination of drugs with other drugsTQB2450 injection is an innovative anti-PD-L1 all-humanized monoclonal antibody developed by Zhengda Qing, and the proposed development of indications includes melanoma, lung cancer, primary large B-cell lymphoma and advanced soft tissue sarcomaIn December last year, Zhengda Suny Register launched a multi-center phase 3 clinical trial of TQB2450 or placebo in conjunction with the Arodini-EC program to treat first-line widespread small cell lung cancerIt's worth noting that the TQB2450 is also the main partner of Thearotini Zheng Daqing has launched the recruitment of patients in Phase 1b clinical studies of the two drugs in combination treatment of recurrent/difficult-to-treat ovarian cancer patients nationwide in January this year Pai Amply monotophoid is a recombinant human-derived anti-PD-1 monoclonal antibody developed by Kangfang Bio In June last year, Kangfang Bio and Zhengda Tianqing spent 689 million yuan to set up a joint venture company to jointly develop the AK105 project and promote the registration and commercialization of the drug It is worth mentioning that the application for a new drug (NDA) for pamphinite has been accepted by CDE for the treatment of patients with recurrent or refractive classic Hodgkin's lymphoma (cHL) who have undergone at least second-line system chemotherapy In addition, Paiampri sing-it-for-all is conducting four registration trials in China for other indications and is expected to submit ndA within the next 1-2 years TQ-B3101 capsule is a small molecular target inhibitor developed and declared by Zhengda Tianqing, registered as a class 1.1 of primary drugs According to the Chinese drug clinical trial registration and information publicity platform, a Phase 2 single-arm, multi-center clinical study evaluating the efficacy and safety of TQ-B3101 capsules for the treatment of ROS1-positive non-small cell lung cancer subjects is recruiting patients Last October, the product was again approved for clinical use in mesomorphic lymphoma kinase (ALK)-positive locally advanced and metastatic non-small cell lung cancer (NSCLC), stomach cancer, lymphoma, etc last June, the TQA3563 tablets were implicitly approved by the NMPA Drug Review Center for the treatment of non-alcoholic fatty hepatitis (NASH) According to the Drug Clinical Trial registration and information disclosure platform, the drug is currently conducting a Phase 1a clinical trial of tolerance and pharmacokinetics in healthy subjects, with a plan to enroll 70 subjects in addition to the above five products, Zhengda Qing and a number of new class 1 drugs have been licensed for CDE clinical trials It involves indications including asthma, as well as a variety of solid and hematomas it is worth mentioning that in May last year, Zhengda Tianqing has reached a strategic cooperation agreement with Platinum Pharmaceuticals to develop and commercialize innovative antibody drugs in the field of cancer immunity and immune diseases we look forward to continuing to bring innovative products to patients that will benefit more patients